NVG-291
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Cord Injury
Conditions
Spinal Cord Injury
Trial Timeline
May 6, 2021 → Jul 3, 2023
NCT ID
NCT05308953About NVG-291
NVG-291 is a phase 1 stage product being developed by NervGen Pharma for Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT05308953. Target conditions include Spinal Cord Injury.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Cord Injury were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05965700 | Phase 1/2 | Recruiting |
| NCT05308953 | Phase 1 | Completed |
Competing Products
20 competing products in Spinal Cord Injury